|
|
 Previous Article | Table of Contents | Next Article 
Effects of interleukin-3 and erythropoietin on in vivo erythropoiesis and
F-cell formation in primates
T Umemura, A al-Khatti, RE Donahue, T Papayannopoulou and G Stamatoyannopoulos
Department of Medicine, School of Medicine, University of Washington,
Seattle.
To test the in vivo cooperativity between interleukin-3 (IL-3) and
erythropoietin (Epo) in stimulating erythropoiesis and hemoglobin F (HbF)
production in primates, we administered recombinant human IL-3 and
recombinant human Epo to baboons and macaques. The effect of these
treatments was assessed by serial bone marrow cultures and by measuring HbF
production in the progeny of bone marrow progenitors and in
peripheral-blood reticulocytes. Administration of IL-3 alone to
hematologically normal or anemic baboons produced an early increase in
erythroid colony-forming units (CFUe) and erythroid clusters (e- clusters)
with an increase in reticulocyte counts and a late increment in the
relative frequency of erythroid burst-forming units (BFUe). In parallel to
the increase in peripheral-blood reticulocytes, IL-3 increased the
frequency of F reticulocytes in the normal and anemic animals. When
administration of IL-3 was followed by administration of Epo, expansion in
all classes of erythroid progenitors and increase in reticulocytes
occurred, beyond the levels observed when the animals were treated with Epo
alone. The combination of IL-3 and Epo, however, did not increase
consistently the rate of F reticulocytes beyond the level induced by Epo
alone. These results suggest that IL-3 enhances the effect of Epo on
erythropoiesis, but the combination of the two growth factors does not lead
to a preferential and significant enhancement of HbF production.
Volume 74,
Issue 5,
pp. 1571-1576,
10/01/1989
Copyright © 1989 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
R. Kurzrock
Thrombopoietic Factors in Chronic Bone Marrow Failure States: The Platelet Problem Revisited
Clin. Cancer Res.,
February 15, 2005;
11(4):
1361 - 1367.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Gabbianelli, U. Testa, A. Massa, E. Pelosi, N. M. Sposi, R. Riccioni, L. Luchetti, and C. Peschle
Hemoglobin switching in unicellular erythroid culture of sibling erythroid burst-forming units: kit ligand induces a dose-dependent fetal hemoglobin reactivation potentiated by sodium butyrate
Blood,
June 1, 2000;
95(11):
3555 - 3561.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Vallera, S.-Y. Seo, A. Panoskaltsis-Mortari, J. D. Griffin, and B. R. Blazar
Targeting myeloid leukemia with a DT390-mIL-3 fusion immunotoxin: ex vivo and in vivo studies in mice
Protein Eng. Des. Sel.,
September 1, 1999;
12(9):
779 - 785.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. P. Rodgers, G. J. Dover, N. Uyesaka, C. T. Noguchi, A. N. Schechter, and A. W. Nienhuis
Augmentation by Erythropoietin of the Fetal-Hemoglobin Response to Hydroxyurea in Sickle Cell Disease
N. Engl. J. Med.,
January 14, 1993;
328(2):
73 - 80.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
K. Geissler, C. Forstinger, P. Kalhs, P. Knobl, P. Kier, P. Kyrle, and K. Lechner
Effect of Interleukin-3 on Responsiveness to Granulocyte-Colony-stimulating Factor in Severe Aplastic Anemia
Ann Intern Med,
August 1, 1992;
117(3):
223 - 225.
[Abstract]
[PDF]
|
|
|
|
|
